Patients with NAFLD have lower plasma levels of BHOB (Mey et al., 2020), which is likely due to the activation of lipogenic pathways such as FAS or Scd1 that transcribes the stearoyl-CoA desaturase-1 (SCD1) enzyme that forms fatty acids and lipid synthesis (Sampath et al., 2007; Flowers and Ntambi, 2009). The gene discussed is SCD; the disease is metabolic dysfunction-associated steatotic liver disease.